2-acetyl-4,9-bis(pivaloxy)-naphtho[2,3-b]furan | 1398505-84-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 萘并呋喃类
• 英文名称: 2-acetyl-4,9-bis(pivaloxy)-naphtho[2,3-b]furan
• 英文别名: 2-acetyl-4,9-bis(pivaloxy)naphtho[2,3-b]furan；4,9-bis(pivalyloxy)naphtho[2,3-b]furan；[2-Acetyl-9-(2,2-dimethylpropanoyloxy)benzo[f][1]benzofuran-4-yl] 2,2-dimethylpropanoate
• CAS: 1398505-84-4
• 化学式: C₂₄H₂₆O₆
• 分子量: 410.467
• InChiKey: FVZAZZPHVGOTMZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  30
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  82.8
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2-acetyl-2,3,4,9-tetrahydronaphtho[2,3-b]furan-4,9-dione 在 sodium dithionite 、 四丁基溴化铵 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 三乙胺 、 锌 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.5h， 生成 2-acetyl-4,9-bis(pivaloxy)-naphtho[2,3-b]furan
  参考文献：
  名称：

  NOVEL ESTERS OF 4, 9-DIHYDROXY-NAPHTHO [2, 3-b] FURANS FOR DISEASE THERAPIES

  摘要：

  本发明公开了4,9-二羟基萘并[2,3-b]呋喃的酯类及其制造和使用方法。本发明还公开了将这些酯转化为体内治疗活性4,9-二羟基萘并[2,3-b]呋喃的方法。本发明进一步公开了包含4,9-二羟基萘并[2,3-b]呋喃的酯类的药物组合物，用于治疗包括增殖性疾病在内的各种疾病。

  公开号：

  US20130345176A1

文献信息

• [EN] NOVEL ESTERS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR DISEASE THERAPIES<br/>[FR] NOUVEAUX ESTERS DE 4,9-DIHYDROXY-NAPHTO[2,3-B]FURANNES POUR TRAITEMENT THÉRAPEUTIQUE DE MALADIES
  申请人：ZHOUSHAN HAIZHONGZHOU XINSHENG PHARMACEUTICALS CO LTD

  公开号：WO2012119265A1

  公开（公告）日：2012-09-13

  The present invention discloses esters of 4,9-dihydroxy-naphtho[2,3-b]furans and methods of making and using the same. The present invention also discloses conversion of the esters into therapeutically active 4,9-dihydroxy-naphtho[2,3-b]furans in vivo. The present invention furthermore discloses pharmaceutical compositions comprising the esters of 4,9- dihydroxy-naphtho[2,3-b]furans for the treatment of various indications including proliferative diseases.

  本发明公开了4,9-二羟基萘并[2,3-b]呋喃的酯类及其制造和使用方法。本发明还公开了将这些酯转化为体内治疗活性4,9-二羟基萘并[2,3-b]呋喃的方法。本发明进一步公开了包含4,9-二羟基萘并[2,3-b]呋喃的酯类的药物组合物，用于治疗包括增殖性疾病在内的各种疾病。
• [EN] TREATMENT OF CANCERS RELATED TO CHRONICALLY ACTIVE RAS<br/>[FR] TRAITEMENT DE CANCERS ASSOCIÉS À UN GÈNE RAS CHRONIQUEMENT ACTIF
  申请人：HANGZHOU YIER BIOTECH CO LTD

  公开号：WO2017079864A1

  公开（公告）日：2017-05-18

  The present invention discloses that naphthofuranquinones and dihydroxynaphthofurans, and derivatives thereof, such as a compound of formula I or II, are effective in deactivating chronically active Ras. The present invention also discloses a method of treating or preventing cancer comprising steps of: 1) identifying a patient suffering from or susceptible to a cancer related to chronically active Ras; and 2) administering a therapeutically effective amount of a compound of formula I or II, or a pharmaceutically acceptable salt thereof. The present invention further discloses a method of treating or preventing cancer comprising steps of: 1) identifying a patient suffering from or susceptible to a cancer related to a K-Ras mutation; and 2) administering a therapeutically effective amount of a compound of formula I or II, or a pharmaceutically acceptable salt thereof.

  本发明揭示了萘呋喹醌和二羟基萘呋喃及其衍生物，例如公式I或II的化合物，在去活化慢性活性Ras方面具有有效性。本发明还揭示了一种治疗或预防癌症的方法，包括以下步骤：1）识别患有或易感患有与慢性活性Ras相关的癌症的患者；和2）给予公式I或II的化合物或其药学上可接受的盐的治疗有效量。本发明还揭示了一种治疗或预防癌症的方法，包括以下步骤：1）识别患有或易感患有与K-Ras突变相关的癌症的患者；和2）给予公式I或II的化合物或其药学上可接受的盐的治疗有效量。
• Substituted naphtho[2,3-b]furans as water-soluble prodrugs for preventing and/or treating cancer
  申请人：BOSTON BIOMEDICAL, INC.

  公开号：US10800752B2

  公开（公告）日：2020-10-13

  The present invention provides compounds represented by formula (1A), or pharmaceutically acceptable salts. Compounds represented by formula (1A), or pharmaceutically acceptable salts thereof, wherein A1 and A2 are identical or different, and each independently —C(═O)B, —C(═O)CR3AR3BB, —CO2B, —C(═S)OB, —CONR3CB, —C(═S)NR3CB, a hydrogen atom, or the like, wherein A1 and A2 are not both hydrogen atoms, wherein B is an optionally substituted 3- to 12-membered monocyclic or polycyclic heterocyclic group, an optionally substituted 3- to 12-membered cyclic amino group, or a group represented by the following formula (B), wherein the 3- to 12-membered monocyclic or polycyclic heterocyclic group and the 3- to 12-membered cyclic amino group have at least one or more secondary nitrogen atoms in the ring; R1 is a hydrogen atom or the like; R2A, R2B, R2C, and R2D are identical or different, and each independently a hydrogen atom or the like; and R8 is alkyl. wherein * denotes a bonding position.

  本发明提供了式(1A)代表的化合物或其药学上可接受的盐。由式(1A)代表的化合物或其药学上可接受的盐，其中A1和A2相同或不同，且各自独立地为-C(═O)B、-C(═O)CR3AR3BB、-CO2B、-C(═S)OB、-CONR3CB、-C(═S)NR3CB、氢原子或类似物，其中A1和A2并非都是氢原子、其中 B 是任选取代的 3 至 12 元单环或多环杂环基团，任选取代的 3 至 12 元环状氨基基团，或下式（B）所代表的基团，其中 3 至 12 元单环或多环杂环基团和 3 至 12 元环状氨基基团在环中至少有一个或多个仲氮原子；R1为氢原子或类似物；R2A、R2B、R2C 和 R2D 相同或不同，且各自独立地为氢原子或类似物；以及 R8 为烷基。 其中 * 表示键合位置。
• NOVEL ESTERS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR DISEASE THERAPIES
  申请人：Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd.

  公开号：EP2681203A1

  公开（公告）日：2014-01-08
• SUBSTITUTED NAPHTHO[2,3-b]FURANS AS WATER-SOLUBLE PRODRUGS FOR PREVENTING AND/OR TREATING CANCER
  申请人：BOSTON BIOMEDICAL, INC.

  公开号：US20190084955A1

  公开（公告）日：2019-03-21

  The present invention provides compounds represented by formula (1A), or pharmaceutically acceptable salts. Compounds represented by formula (1A), or pharmaceutically acceptable salts thereof, wherein A 1 and A 2 are identical or different, and each independently —C(═O)B, —C(═O)CR 3A R 3B B, —CO 2 B, —C(═S)OB, —CONR 3C B, —C(═S)NR 3C B, a hydrogen atom, or the like, wherein A 1 and A 2 are not both hydrogen atoms, wherein B is an optionally substituted 3- to 12-membered monocyclic or polycyclic heterocyclic group, an optionally substituted 3- to 12-membered cyclic amino group, or a group represented by the following formula (B), wherein the 3- to 12-membered monocyclic or polycyclic heterocyclic group and the 3- to 12-membered cyclic amino group have at least one or more secondary nitrogen atoms in the ring; R 1 is a hydrogen atom or the like; R 2A , R 2B , R 2C , and R 2D are identical or different, and each independently a hydrogen atom or the like; and R 8 is alkyl. wherein * denotes a bonding position.